quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:36:45·28d
SECFiling
Rein Therapeutics Inc. logo

SEC Form 10-K filed by Rein Therapeutics Inc.

RNTX· Rein Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • RNTX
    Rein Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Sep 22UpdateH.C. Wainwright$10.00
  • Jan 28UpdateRodman & Renshaw$8.00

Related

  • PR52d
    Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
  • SEC53d
    Rein Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
  • SEC63d
    SEC Form 8-K filed by Rein Therapeutics Inc.
  • PR94d
    Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
  • SEC97d
    Rein Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
  • SEC133d
    SEC Form 8-K filed by Rein Therapeutics Inc.
  • INSIDER156d
    Large owner Voss Capital, Lp bought $127,593 worth of shares (104,183 units at $1.22) (SEC Form 4)
  • SEC161d
    SEC Form 10-Q filed by Rein Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022